Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Anvs save search
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
Published: 2023-10-30 (Crawled : 23:00) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: -0.12%
H: 3.62%
C: 1.88%
disease alzheimer’s positive buntanetap trial
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
Published: 2023-10-12 (Crawled : 12:00) - globenewswire.com
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 3.9%
H: 17.44%
C: 5.13%
alzheimer’s positive study
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
Published: 2023-07-18 (Crawled : 14:20) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 1.63%
H: 1.99%
C: 0.36%
drug conference association positive international alzheimer's
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
Published: 2023-06-20 (Crawled : 21:00) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: -0.97%
H: 9.35%
C: 6.25%
disease positive buntanetap parkinson’s trial
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 11.24%
H: 7.12%
C: 1.69%
fda disease trial positive buntanetap anvs401 posiphen phase 3
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Published: 2022-01-25 (Crawled : 17:00) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 2.75%
H: 5.63%
C: -1.27%
fda parkinson disease positive phase 3 buntanetap
Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease
Published: 2021-10-05 (Crawled : 14:15) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 3.69%
H: 5.15%
C: -16.27%
disease treatment phase 2 positive parkinson
Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease
Published: 2021-07-30 (Crawled : 16:00) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: -13.77%
H: 0.0%
C: 0.0%
disease alzheimer treatment ongoing clinical trials positive results parkinson trial alzheimer’s alzheimer's disease alzheimer's posiphen anvs401
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Published: 2021-05-21 (Crawled : 18:00) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 39.81%
H: 165.43%
C: 62.56%
disease alzheimer phase 2 positive alzheimer’s alzheimer's disease alzheimer's anvs401
Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
Published: 2021-03-16 (Crawled : 17:00) - biospace.com/
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 19.94%
H: 17.68%
C: -18.34%
phase 2 positive parkinson anvs401
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.